Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

NCT05577728 · clinicaltrials.gov ↗

COMPLETED

Status

2316

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: New use of semaglutide injection
DRUG: New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)

Sponsor

Brigham and Women's Hospital